Although Zhang et al. also suggested that cinobufagin suppressed the progression of four NSCLC cell lines through AKT signaling pathway 34, they did not identify this action in vivo which were further studied in our work. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.